

Machine learning in healthcare: How metabolic biomarkers can be identified to diagnose diseases

Dr. Sindy Neumann, numares AG

One Sample – All Answers

Advanced. Automated. Affordable.



numares is a NMR diagnostics company
shaping future diagnostics using
Metabolomics and Machine Learning for
software-controlled
multimarker diagnostics

2004

Funded: 2004 as a
spin-off of
Institute of
Biophysics &
Physical
Biochemistry of
Regensburg
University

60+

Employees, 12
nationalities, with
backgrounds in
medicine,
biochemistry,
physics,
computational science


Patents

15 patent
families,
30+ peer-
reviewed
publications,
several ongoing
clinical studies

2

Locations
worldwide:
Boston, USA
Regensburg,
Germany


AI applications in healthcare




Introduction to Metabolomics

[Gonzalez-Covarrubias et al. 2022; Zhang et al. 2015; Zhang et al. 2020]


- **Definition:** study of small molecules, commonly known as metabolites, within an organism
- **Matrices:** cells, tissues, body fluids (urine, serum, plasma, CSF etc.)
- **Applications:**
Nutrition Science, Drug Development,
Diagnostics: Alzheimer's disease,
Diabetes, Prostate cancer, CVD etc.
→ **Clinical metabolomics**
- **Technology:** Mass spectrometry (MS),
NMR (nuclear magnetic resonance)



Source: <https://www.frontiersin.org/articles/10.3389/fchem.2019.00319/full>




Source: <https://www.mtidx.com/our-technology/metabolomics>




Different chemical environments cause the NMR signal to be slightly “out of tune” with nominal resonance frequency (chemical shift)
→ NMR spectrum


- One substance can be associated with one or multiple signals
- Integrals of signals are proportional to concentrations of corresponding substances




NMR data can be quite challenging




- Dirty (background etc.)
- Noisy
- Redundant (multi-collinearity)
- Variations in chemical shift





Noise, Shifts, Overlaps





Complex Correlation Structure





NMR data needs to be processed



REFERENCING




PHASE CORRECTION




BACKGROUND TREATMENT


NMR data needs to be processed (cont.)




Chemische Verschiebung ppm]




BINNING



NOISE REGIONS



SPECTRAL FITTING



Source: <https://www.scielo.br/j/aem/a/yqQ9KFBbVwJPsdWDwMkSwB/?lang=en#>

Translation into
clinical practice

Analysis of metabolomics data

[Corsaro et al. 2022; Debik et al. 2021; Pomyen et al. 2020]

Data (Pre-) Processing




- Phasing
- Baseline correction
- Binning
- Normalization
- Scaling
- Transformation
- Outlier detection
- Missing value imputation
- Etc.

Data Analysis

- **Univariate testing:** t-Test, ANOVA, chi-square ...
- **Dimensionality reduction:** PCA, PLS
- **Clustering:** k-means, SOMs
- **Regression:** PCR, PLS
- **Classification:** (O)PLS-DA, SVM, RF, logistic regression
- Etc.

Biological interpretation


- Pathway analysis: ORA, FCS




Deep Learning: application still limited, in particular data pre-processing (CNNs!), more comprehensive applications in other omic domains

Opportunities and Challenges of Clinical Metabolomics


[Gonzalez-Covarrubias et al. 2022; Tebani et al. 2016; Zhang et al. 2015]



Garbage in, garbage out ...




[Source: xkcd]




Big Data versus Smart Data


Data are the enabler but also the issue





Translation into clinical practice (Registration and Regulations)





HOW TO REGISTER A MEDICAL DEVICE IN EUROPE


- **1. CE mark strategic plan**


It is highly recommended to establish a strategic plan from the beginning of the cycle of a medical device, as it will affect all the decisions taken during the process.
- **2. Define intended use and product classification.**

It is very important to confirm the correct classification of your product with the chosen notified body before starting the assessment procedure.
- **3. Quality Management System (QMS) and Conformity with essential requirements**

It determines the quality requirements and how the product will be tested.
- **4. Conformity assessment procedure**

There are several paths to obtain the CE mark, depending on the medical device classification.
- **5. Dossier-technical documentation**

including all information about device description, manufacturing process, and pre-clinical and clinical data.
- **6. Application evaluation to a Notified body (if applicable)**

The application should include: the technical file and Application form.
- **7. Get approval and CE mark**

The Conformité Européenne Mark (CE mark) is the symbol that indicates that the product has been assessed to meet high safety, health and environmental protection requirements.



Europe

- requires CE mark!
- QMS necessary (ISO 13485)
- Conformity assessments (CE mark certifies that medical device complies with MDR/IVDR)
- Regulations:
MDR ((EU) 2017/745),
IVDR ((EU) 2017/746)
- 4 risk classes according to MDR (risk I, IIa, IIb, III)
- 4 risk classes according to IVDR (A, B, C, D)
- Notified body (e.g. TÜV)

USA

- Responsible: FDA
- Types of submission:
 - Premarket Notification (510k)
 - Premarket Approval (PMA)
 - De Novo


[Source: <https://leonresearch.com/medical-devices-europe-mdr-2017-745/>]



Good Machine Learning Practice for Medical Device Development: Guiding Principles

- | | |
|--|---|
| 1 Multi-Disciplinary Expertise Is Leveraged Throughout the Total Product Life Cycle | 2 Good Software Engineering and Security Practices Are Implemented |
| 3 Clinical Study Participants and Data Sets Are Representative of the Intended Patient Population | 4 Training Data Sets Are Independent of Test Sets |
| 5 Selected Reference Datasets Are Based Upon Best Available Methods | 6 Model Design Is Tailored to the Available Data and Reflects the Intended Use of the Device |
| 7 Focus Is Placed on the Performance of the Human-AI Team | 8 Testing Demonstrates Device Performance During Clinically Relevant Conditions |
| 9 Users Are Provided Clear, Essential Information | 10 Deployed Models Are Monitored for Performance and Re-training Risks are Managed |

<https://medicalfuturist.com/fda-approved-ai-based-algorithms/>



[Source: Benjamins S, Dhunoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. *NPJ Digit Med*. 2020;3:118. Published 2020 Sep 11. doi:10.1038/s41746-020-00324-0]

- Corsaro et al. *NMR in metabolomics: from conventional statistics to machine learning and neural network approaches*. Appl. Sci. **2022**, 12(6)
- Debik et al. *Multivariate analysis of NMR-based metabolomic data*. NMR in Biomedicine **2021**, 35(10)
- Gonzalez-Covarrubias V, Martinez-Martinez E, Del Bosque-Plata L. *The potential of metabolomics in biomedical applications*. Metabolites **2022**, 12(2)
- Pomyen et al. *Deep metabolome: applications of deep learning in metabolomics*. Comput Struct Biotechnol J. **2020**
- Tebani et al. *Clinical Metabolomics: the new metabolic window for inborn errors of metabolism investigations in the post-genomic era*. Int. J. Mol. Sci. **2016**, 17(7)
- Zhang et al. *Metabolomics for biomarker discovery: moving to the clinic*. Biomed Res Int. **2015**
- Zhang et al. *Mass spectrometry-based metabolomics in health and medical science: a systematic review*. RSC Adv. **2020**



numares
H E A L T H

Thank you for your attention



Dr. Cindy Neumann

Head of Biostatistics, numares AG

sindy.neumann@numares.com